Replies to post #297664 on Avid Bioservices Inc (CDMO)

[north40000]

Worth a repeat, from your 1st link:

"Durvalumab is being evaluated in combination with bavituximab in pretreated, advanced NSCLC patients. Bavituximab is an inhibitor of phosphatidylserine which is an immunosuppressive molecule expressed on tumor cells and exosomes in the tumor microenvironment. Bavituximab has shown improvement in median OS in nonsquamous, pretreated, advanced NSCLC patients with combination with docetaxel over control (11.7 versus 7.3 months). Early phase trials will evaluate bavituximab in combination with durvalumab until progression or toxicity, with a primary endpoint of ORR, and secondary endpoints of PFS, OS, and safety [54]."

******************

"Newer combinations are also being evaluated such as pembrolizumab plus ipilimumab in the pretreated NSCLC population or durvalumab plus tremelimumab in the treatment-naïve population. IDO inhibition with indoximod will be evaluated in various treatment settings alone and in combination with PD-1/PD-L1 inhibition. Pembrolizumab will be evaluation in the stage III setting with chemoradiation along with azacitadine, a PIK3-gamma inhibitor and an HDAC inhibitor in the pretreated, advanced population. Nivolumab will be evaluated in combination with a whole-cell vaccine, and durvalumab will be evaluated in combination with a phosphatidylserine inhibitor in the pretreated, advanced population.